400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR1900022366
尚未开始
/
/
/
2019-04-08
/
/
非ST段抬高型心肌梗死
非ST段抬高型心肌梗死患者三甲胺氮氧化物与冠状动脉粥样硬化负荷的关系
非ST段抬高型心肌梗死患者三甲胺氮氧化物与冠状动脉粥样硬化负荷的关系
518055
Aims to evaluate the relationship between plasma TMAO levels, and the complexity and atherosclerotic burden in NSTEMI patients.
连续入组
其它
N/A
N/A
中国医学科学院阜外医院深圳医院
/
100
/
2019-04-15
2020-04-15
/
The present study will include two groups of individuals. The first group will include one hundred NSTEMI patients older than 18 years, those who will undergo emergency or primary coronary angiography or percutaneous coronary intervention (PCI) from 15th April 2019 to 15th April 2020. NSTEMI will define according to current ESC guideline as the presence of acute chest pain, but no persistent ST-segment elevation; electrocardiogram (ECG) change may include ST-segment depression ≥0.05 mV, T-wave inversion ≥0.3 mV or flat T wave, or transient ST-segment elevation ≤0.05 mV or may be normal ECG; and positive elevated troponin T or I and/or CK-MB exceeding the upper limit of normal range. The second group will include healthy individuals without known cardiovascular diseases those who will visit for health screen. The second group purpose will provide the reference interval values for TMAO levels compared to the first group.;
请登录查看The exclusion criteria comprises; ST elevation myocardial infarction or stable or unstable coronary artery disease, heart failure, renal or hepatic disease, severe valvular disease, previous history of PCI or CABG, history stroke or bleeding within 3 months, peripheral arterial disease, pregnancy, chronic obstructive lung disease, acute and chronic infection, and history of cancer.;
请登录查看中国医学科学院阜外医院深圳医院
518055
求实药社2026-03-05
生物制品圈2026-03-05
医药观澜2026-03-05
医药观澜2026-03-05
河北省干细胞中心2026-03-05
生物制药小编2026-03-05
一度医药2026-03-05
炎明生物Pyrotech2026-03-05
药明康德2026-03-05
疑夕随笔2026-03-04